文献速递脑血管病神经重症与神经感染

大缺血核心患者替奈普酶或阿替普酶桥接治疗后的功能结局与出血率

Functional Outcome and Hemorrhage Rates After Bridging Therapy With Tenecteplase or Alteplase in Patients With Large Ischemic Core.
PubMed 文献 · Neurology · 2024-06-11

该回顾性多中心登记研究纳入647例前循环大血管闭塞且DWI-ASPECTS≤5的患者,比较机械取栓前替奈普酶(n=194)与阿替普酶(n=453)桥接治疗。

核心结论

  • 在常规临床实践中,对于大血管闭塞且大缺血核心的卒中患者,桥接治疗中使用替奈普酶相比阿替普酶在疗效方面令人鼓舞、在安全性方面令人放心。
  • 这些结果支持将替奈普酶作为大缺血核心患者桥接治疗中阿替普酶的替代选择加以考虑。

研究设计与样本

  • 回顾性分析TETRIS(替奈普酶)和ETIS(阿替普酶)法国多中心登记研究中前循环大血管闭塞且DWI-ASPECTS≤5、机械取栓前接受替奈普酶或阿替普酶治疗的患者。
  • 共分析647例患者(替奈普酶组n=194;阿替普酶组n=453;纳入期2015-2022年)。
  • 使用倾向评分重叠加权以减少治疗组间基线差异。

主要发现

  • 中位(四分位距)年龄71(57-81)岁,NIH卒中量表评分19(16-22),DWI-ASPECTS 4(3-5),最后正常至静脉溶栓时间和穿刺时间分别为165分钟(130-226)和260分钟(203-349)。
  • 机械取栓后成功再灌注率为83.1%。
  • 倾向评分重叠加权后,两组所有基线变量均衡良好。

关键数值与推荐

  • 主要结局为3个月残疾减轻(改良Rankin量表有序分析)。
  • 安全性结局为3个月死亡率、脑实质血肿和症状性颅内出血。
  • 本研究提供III级证据:前循环大血管闭塞且DWI-ASPECTS≤5的患者,机械取栓前接受替奈普酶相比阿替普酶,3个月功能结局更好且死亡率更低。

临床怎么用

  • 作者认为,这些结果支持将替奈普酶作为大缺血核心患者桥接治疗中阿替普酶的替代选择加以考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: IV tenecteplase is an alternative to alteplase before mechanical thrombectomy (MT) in patients with large-vessel occlusion (LVO) ischemic stroke. Little data are available on its use in patients with large ischemic core. We aimed to compare the efficacy and safety of both thrombolytics in this population. METHODS: We conducted a retrospective analysis of patients with anterior circulation LVO strokes and diffusion-weighed imaging Alberta Stroke Program Early CT Score (DWI-ASPECTS) ≤5 treated with tenecteplase or alteplase before MT from the TETRIS (tenecteplase) and ETIS (alteplase) French multicenter registries. Primary outcome was reduced disability at 3 months (ordinal analysis of the modified Rankin scale [mRS]). Safety outcomes were 3-month mortality, parenchymal hematoma (PH), and symptomatic intracranial hemorrhage (sICH). We used propensity score overlap weighting to reduce baseline differences between treatment groups. RESULTS: We analyzed 647 patients (tenecteplase: n = 194; alteplase: n = 453; inclusion period 2015-2022). Median (interquartile range) age was 71 (57-81) years, with NIH Stroke Scale score 19 (16-22), DWI-ASPECTS 4 (3-5), and last seen well-to-IV thrombolysis and puncture times 165 minutes (130-226) and 260 minutes (203-349), respectively. After MT, the successful reperfusion rate was 83.1%. After propensity score overlap weighting, all baseline variables were well balanced between both treatment groups. Compared with patients treated with alteplase, patients treated with tenecteplase had better 3-month mRS (common odds ratio [OR] for reduced disability: 1.37, 1.01-1.87, p = 0.046) and lower 3-month mortality (OR 0.52, 0.33-0.81, p < 0.01). There were no significant differences between thrombolytics for PH (OR 0.84, 0.55-1.30, p = 0.44) and sICH incidence (OR 0.70, 0.42-1.18, p = 0.18). DISCUSSION: Our data are encouraging regarding the efficacy and reassuring regarding the safety of tenecteplase compared with that of alteplase in bridging therapy for patients with LVO strokes and a large ischemic core in routine clinical care. These results support its consideration as an alternative to alteplase in bridging therapy for patients with large ischemic cores. TRIALS REGISTRATION INFORMATION: NCT03776877 (ETIS registry) and NCT05534360 (TETRIS registry). CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that patients with anterior circulation LVO stroke and DWI-ASPECTS ≤5 treated with tenecteplase vs alteplase before MT experienced better functional outcomes and lower mortality at 3 months.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gerschenfeld G, Turc G, Obadia M, et al. Functional Outcome and Hemorrhage Rates After Bridging Therapy With Tenecteplase or Alteplase in Patients With Large Ischemic Core. Neurology. 2024. PMID: 38862134. doi:10.1212/WNL.0000000000209398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。